Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Inotiv, Inc. is a U.S.-based contract research organization (CRO) that provides nonclinical and analytical drug discovery and development services to pharmaceutical, biotechnology, medical device, and academic customers. The company operates within the preclinical research, drug discovery, and nonclinical safety assessment segments of the life sciences industry. Its core offerings support early-stage research through regulatory submission, with revenue primarily driven by outsourced research services for drug development programs.
The company’s primary business lines include in vivo and in vitro pharmacology studies, toxicology and safety assessment, bioanalytical services, and related research support. Inotiv serves a diversified customer base ranging from emerging biotechnology firms to large pharmaceutical companies, with a strategic emphasis on integrated, end-to-end nonclinical capabilities. The company traces its origins to 1988 under its former name, Bioanalytical Systems, Inc., and adopted the Inotiv name in 2021 following its acquisition of Envigo. Since that acquisition, Inotiv has undergone strategic restructuring to focus on higher-margin CRO services.
Business Operations
Inotiv organizes its operations primarily around two reportable business segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment represents the company’s core CRO platform and includes nonclinical toxicology, pharmacology, and bioanalytical testing services that support regulatory submissions. This segment generates the majority of the company’s revenue and is central to its long-term strategy.
The RMS segment historically included the breeding and supply of research models and related services. Following regulatory challenges and operational disruptions associated with legacy Envigo facilities, Inotiv initiated divestitures and wind-downs of significant portions of the RMS business between 2023 and 2024. The company operates laboratories and research facilities primarily in the United States and Europe and relies on specialized scientific personnel, proprietary methodologies, and regulated laboratory infrastructure to deliver services.
Strategic Position & Investments
Inotiv’s strategic direction is focused on simplifying operations, reducing leverage, and concentrating capital and management resources on its CRO-based Discovery and Safety Assessment platform. Key initiatives have included divesting non-core RMS assets, exiting underperforming facilities, and strengthening compliance and quality systems. These actions are intended to stabilize cash flow and improve operating margins.
The acquisition of Envigo remains the most significant investment in the company’s history, materially expanding Inotiv’s scale and service breadth but also introducing operational and regulatory complexity. Since 2023, management has emphasized balance sheet repair, debt reduction, and operational discipline rather than additional large-scale acquisitions. The company continues to invest selectively in analytical technologies, in vivo pharmacology capabilities, and expanded regulatory support services to enhance competitiveness in early-stage drug development.
Geographic Footprint
Inotiv is headquartered in North America, with its corporate headquarters located in the United States. The company maintains a substantial operational presence across the U.S., which represents its largest revenue-generating region, supported by multiple laboratory and research facilities.
Internationally, Inotiv operates in Europe, including facilities in the United Kingdom and other European markets, supporting multinational pharmaceutical and biotechnology clients. While the company’s geographic reach is narrower than that of larger global CROs, its international footprint allows it to participate in cross-border research programs and serve customers with global development strategies.
Leadership & Governance
Inotiv is led by an executive team with experience in contract research, life sciences operations, and corporate restructuring. Leadership has emphasized operational accountability, regulatory compliance, and strategic focus following the company’s post-acquisition challenges. The board of directors oversees governance, capital allocation, and risk management, with increased attention to compliance and operational oversight.
Key members of the leadership team include:
- Robert Leasure – President and Chief Executive Officer
- David Smith – Chief Financial Officer
- Lori Johnson – Chief Operating Officer
- Natalie Thomas – Chief Legal and Compliance Officer
Management has articulated a strategic vision centered on restoring financial stability, strengthening customer relationships, and positioning Inotiv as a specialized, high-quality provider of nonclinical CRO services.